Opinion
Video
Author(s):
Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.
Video content above is prompted by the following:
Dr Iams: Please provide your insights on outcomes from the ongoing Phase I ARTEMIS-001[study into which 11 of 53 (20.75%) patients with small cell lung cancer were enrolled.